204 results on '"Rigby W"'
Search Results
2. POS0051 DIFFERENTIAL PHARMACODYNAMIC ALTERATIONS AFTER TREATMENT WITH ABATACEPT OR ADALIMUMAB IN MTX-INADEQUATE RESPONDER PATIENTS WITH EARLY RA: WHOLE BLOOD RNA-SEQ ANALYSIS OF THE EARLY AMPLE STUDY
3. Assessment of lipid changes and infection risk in diabetic and nondiabetic patients with rheumatoid arthritis treated with tofacitinib.: 184.
4. Woolgrowers Field, Towcester, Northamptonshire
5. Effet des allèles HLA-DRB1 à risque sur l’efficacité et la tolérance de l’abatacept chez des patients ayant une PR récente modérée à sévère, immunopositifs, naïfs de biologiques et traités par abatacept ou adalimumab : données issues de « EARLY AMPLE »
6. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial
7. Reduced frequency and severity of infusion-related adverse events after change in ofatumumab infusion regimen: comment on the article by ϕstergaard et al
8. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
9. Low-Avidity Autoantibodies against Bactericidal/Permeability-Increasing Protein Occur in Gram-Negative and Gram-Positive Bacteremia
10. FRI0115 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, AND HEALTH-RELATED QUALITY OF LIFE, AND REDUCED FATIGUE OVER TIME IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ARE METHOTREXATE-NAÏVE: RESULTS FROM THE FINCH 3 STUDY
11. SAT0158 EFFICACY AND SAFETY OF FILGOTINIB IN METHOTREXATE-NAÏVE PATIENTS WITH RHEUMATOID ARTHRITIS: FINCH 3 52-WEEK RESULTS
12. THU0213 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 84 WEEKS FROM THE SELECT-MONOTHERAPY STUDY
13. THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
14. THU0160 THE EFFECT OF HLA-DRB1 RISK ALLELES ON THE CLINICAL EFFICACY AND SAFETY OF ABATACEPT IN SEROPOSITIVE, BIOLOGIC-NAÏVE PATIENTS WITH EARLY, MODERATE-TO-SEVERE RA TREATED WITH ABATACEPT OR ADALIMUMAB: DATA FROM THE OPEN-LABEL SWITCH PERIOD OF THE HEAD-TO-HEAD SINGLE-BLINDED ’EARLY AMPLE’ TRIAL
15. THU0195 INCIDENCE AND RISK OF VENOUS THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ENROLLED IN THE UPADACITINIB SELECT CLINICAL TRIAL PROGRAM
16. P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
17. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximabʼs Efficacy in MTX iNadequate rEsponders (SERENE))
18. Synthetic studies of pentamethylclopentadienylrodium complexes
19. 060 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate
20. SAT0168 Mri results following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized controlled trial
21. OP0035 Upadacitinib as monotherapy: a phase 3 randomised controlled double-blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate
22. AB0448 Patient-reported outcomes following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomised controlled trial
23. UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 260 WEEKS FROM THE SELECT-MONOTHERAPY STUDY.
24. Adolescent idiopathic scoliosis: the possible harm of bracing and the likely benefit of exercise
25. FRI0222 Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized controlled trial (COMP-ACT)
26. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
27. FRI0110 Assessment of Immunogenicity of Live Zoster Vaccination in Rheumatoid Arthritis Patients on Background Methotrexate before and after Initiating Tofacitinib or Placebo
28. Does bracing affect bone health in women with adolescent idiopathic scoliosis?
29. SAT0226 Tocilizumab (TCZ) as Combination Therapy and as Monotherapy VS Methotrexate (MTX) in MTX-Naive Patients with Early Rheumatoid Arthritis: Patient-Reported Outcomes (PROS) from A Randomized, Placebo-Controlled Trial
30. Reply to 'Reduced frequency and severity of infusion-related adverse events after change in ofatumumab infusion regimen: comment on the article by Østergaard et al'
31. Reduced frequency and severity of infusion-related adverse events after change in ofatumumab infusion regimen - Reply to comment by Abeles (letter)
32. OP0041 Tocilizumab (TCZ) in Combination and Monotherapy Versus Methotrexate (MTX) in MTX-Naive Patients (PTS) with Early Rheumatoid Arthritis (RA): Clinical and Radiographic Outcomes from a Randomised, Placebo-Controlled Trial
33. Clothe the Soldier Prototype K1 Load Carriage System Design Assessment using the APLCS Load Carriage Simulator
34. Clothe the Soldier Prototype Modular Load Carriage System Design Assessment using the APLCS Load Carriage Simulator
35. Reply
36. Narrow Training for Broad Functioning
37. Approach and avoidance gradients and conflict behavior in a predominantly temporal situation
38. Post-transcriptional regulation of tumor necrosis factor alpha expression
39. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3.
40. History, 1924 to 1972, of the Division of Consulting Psychology.
41. Filters for cell culture
42. An Anodizing Process for the Production of Inorganic Microfiltration Membranes
43. 345. Gamboge. Part I. The constitutions of the acids C11H10O4 and C12H10O6 derived from gambogic acid.
44. 579. Marrubiin. Part II. Correlation with ambreinolide.
45. 578. Marrubiin. Part I. Oxidation products.
46. Notes.
47. 389. Oxidations with sodium bismuthate : glycol fission and related reactions.
48. Gamboge. Part V. Synthesis of 2′-isopropyl-5′-methylbiphenyl-2,4,6-triol.
49. Gamboge. Part IV. Scission of gambogic acid by alkali.
50. Aurofusarin.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.